EE200200241A - Suhkurtõvevastane preparaat ja meetod - Google Patents

Suhkurtõvevastane preparaat ja meetod

Info

Publication number: EE200200241A
Authority: EE; Estonia
Prior art keywords: antidiabetic agent; antidiabetic; agent
Prior art date: 1999-11-03

Application number

EEP200200241A

Other languages

English (en)

Inventor

Anne Piper Beth

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-03

Filing date

2000-10-13

Publication date

2003-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23716278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200200241(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-10-13 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2003-12-15 Publication of EE200200241A publication Critical patent/EE200200241A/et

2009-10-15 Publication of EE05210B1 publication Critical patent/EE05210B1/et

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

EEP200200241A 1999-11-03 2000-10-13 Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis EE05210B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/432,465 US6586438B2 (en)	1999-11-03	1999-11-03	Antidiabetic formulation and method
PCT/US2000/028467 WO2001032158A2 (en)	1999-11-03	2000-10-13	Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent

Publications (2)

Publication Number	Publication Date
EE200200241A true EE200200241A (et)	2003-12-15
EE05210B1 EE05210B1 (et)	2009-10-15

Family

ID=23716278

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200241A EE05210B1 (et)	1999-11-03	2000-10-13	Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis

Country Status (34)

Country	Link
US (2)	US6586438B2 (et)
EP (1)	EP1253944A2 (et)
JP (2)	JP2003529551A (et)
KR (2)	KR20020050253A (et)
CN (3)	CN101273981B (et)
AR (1)	AR026355A1 (et)
AU (1)	AU781781B2 (et)
BG (2)	BG106732A (et)
BR (1)	BR0015295A (et)
CA (1)	CA2389931A1 (et)
CZ (2)	CZ20021547A3 (et)
DE (1)	DE60038455T2 (et)
EE (1)	EE05210B1 (et)
ES (1)	ES2302702T3 (et)
GE (2)	GEP20053539B (et)
HK (1)	HK1045655A1 (et)
HU (1)	HUP0300642A3 (et)
IL (3)	IL149138A0 (et)
LT (1)	LT5025B (et)
LV (1)	LV12907B (et)
MX (1)	MXPA02004290A (et)
MY (2)	MY125118A (et)
NO (1)	NO20022086L (et)
NZ (1)	NZ552074A (et)
PL (1)	PL366112A1 (et)
RO (1)	RO123109B1 (et)
RU (1)	RU2276604C2 (et)
SK (1)	SK4992002A3 (et)
TN (2)	TNSN00206A1 (et)
TW (1)	TWI241185B (et)
UA (2)	UA76706C2 (et)
UY (1)	UY26425A1 (et)
WO (1)	WO2001032158A2 (et)
ZA (2)	ZA200203367B (et)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235627B2 (en) *	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6414002B1 (en) *	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030040469A1 (en) *	2000-03-08	2003-02-27	Knudsen Liselotte Bjerre	Lowering serum lipids
EP1283054A4 (en) *	2000-03-17	2006-04-12	Ajinomoto Kk	MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
FR2816840B1 (fr)	2000-11-17	2004-04-09	Flamel Tech Sa	Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7062312B2 (en) *	2001-01-17	2006-06-13	Pediamed Pharmaceuticals, Inc.	Combination and method including a visual marker for determining compliance with a medication regimen
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20030022816A1 (en) *	2001-03-07	2003-01-30	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
FR2825023B1 (fr) *	2001-05-23	2005-04-15	Flamel Tech Sa	Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
EP1435931A2 (en) *	2001-09-28	2004-07-14	Sun Pharmaceuticals Industries Ltd.	Dosage form for treatment of diabetes mellitus
US6924311B2 (en) *	2001-10-17	2005-08-02	X-Ceptor Therapeutics, Inc.	Methods for affecting various diseases utilizing LXR compounds
US7183321B2 (en) *	2001-12-17	2007-02-27	Bristol-Myers Squibb Company	Antidiabetic formulation and method
DE60219963T2 (de)	2002-01-25	2008-02-07	Laboratorios Silanes, S.A. De C.V.	Pharmazeutische zusammensetzung, die zur glukosekontrolle im blut von patienten mit diabetes typ 2 eingesetzt wird
EP1492511B3 (fr)	2002-04-09	2012-05-02	Flamel Technologies	Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
AU2002356419A1 (en)	2002-06-17	2003-12-31	Themis Laboratories Private Limited	Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
DK1525219T3 (da) *	2002-07-04	2009-09-07	Zealand Pharma As	GLP-1 og fremgangsm der til behandling af diabetes
JP2004067575A (ja) *	2002-08-06	2004-03-04	Yaizu Suisankagaku Industry Co Ltd	糖尿病治療薬効果促進剤
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE526943C2 (sv) *	2002-08-26	2005-11-22	Indevex Ab	Födoämneskompositionsprodukt
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) *	2003-01-29	2004-07-29	Rao Vinay U.	Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
PT1558220E (pt) *	2003-07-24	2010-03-12	Rasendrakumar Jha	Composições orais para tratamento da diabetes
PL1648933T3 (pl) *	2003-07-25	2010-01-29	Conjuchem Biotechnologies Inc	Długo działające pochodne insuliny i związane z tym sposoby
US20050202063A1 (en) *	2003-08-26	2005-09-15	Ebn International Kft	Food product
US20050163842A1 (en) *	2003-12-31	2005-07-28	Garth Boehm	Rosiglitazone and metformin formulations
US20050163837A1 (en) *	2003-12-31	2005-07-28	Garth Boehm	Rosiglitazone formulations
CA2564750A1 (en) *	2004-04-29	2005-11-17	Andrx Labs, Llc	Controlled release metformin compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100760430B1 (ko) *	2004-12-31	2007-10-04	한미약품 주식회사	당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
WO2006074278A2 (en) *	2005-01-05	2006-07-13	Mitsunori Ono	Compositions for treating diabetes or obesity
CN101111266A (zh) *	2005-01-31	2008-01-23	味之素株式会社	含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
US20090227493A1 (en) *	2005-05-27	2009-09-10	Daiichi Sankyo Company, Limited	Combined drug for treating diabetes
RU2308265C2 (ru) *	2005-07-25	2007-10-20	Илья Николаевич Медведев	Способ выбора лечения тромбоцитопатии при метаболическом синдроме
EP2737897A3 (en) *	2005-12-09	2014-10-01	Metaproteomics, LLC	Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
AU2006330332B2 (en) *	2005-12-28	2012-03-08	Takeda Pharmaceutical Company Limited	Therapeutic agent for diabetes
FR2896157B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
MX2008014024A (es)	2006-05-04	2008-11-14	Boehringer Ingelheim Int	Formas poliformas.
CA2659012A1 (en) *	2006-07-26	2008-01-31	Diamedica Inc.	Methods of diagnosis and treatment for metabolic disorders
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US20100136561A1 (en) *	2008-05-16	2010-06-03	Interleukin Genetics, Inc.	Genetic Markers for Weight Management and Methods of Use Thereof
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101189639B1 (ko) *	2008-12-15	2012-10-12	씨제이제일제당 (주)	메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
EP2732818B1 (en)	2009-03-31	2017-05-03	Ligand Pharmaceuticals Inc.	A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis
US20120100208A1 (en)	2009-04-29	2012-04-26	Amarin Pharma, Inc.	Stable pharmaceutical composition and methods of using same
US20120093922A1 (en)	2009-04-29	2012-04-19	Amarin Corporation Plc	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG177254A1 (en)	2009-06-15	2012-02-28	Ian Osterloh	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
CN107115530A (zh)	2009-11-27	2017-09-01	勃林格殷格翰国际有限公司	基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
CN101810628B (zh) *	2010-04-13	2012-05-23	北京四环科宝制药有限公司	二甲双胍格列吡嗪片及其制备方法
CN103003300B (zh)	2010-04-27	2017-06-09	西兰制药公司	Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
CA2797310C (en)	2010-05-05	2020-03-31	Boehringer Ingelheim International Gmbh	Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
ES2596291T3 (es)	2010-05-11	2017-01-05	Janssen Pharmaceutica, N.V.	Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012074930A2 (en)	2010-11-29	2012-06-07	Amarin Pharma, Inc.	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012090225A2 (en) *	2010-12-29	2012-07-05	Nutracryst Therapeutics Private Limited	Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
CA2823397C (en)	2011-01-07	2020-03-10	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
BR112014010780A2 (pt)	2011-11-03	2017-04-25	Zealand Pharma As	conjugados do peptídeo agonista do receptor glp-1-gastrina
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
KR20190120430A (ko)	2012-01-06	2019-10-23	엘셀릭스 테라퓨틱스 인코포레이티드	바이구아나이드 조성물 및 대사 장애를 치료하는 방법
AU2013207329B2 (en)	2012-01-06	2017-10-26	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
WO2013115742A1 (en) *	2012-01-31	2013-08-08	Mahmut Bilgic	Pharmaceutical composition comprising alpha-glucosidase inhibitor
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP4151218A1 (en)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013173923A1 (en)	2012-05-25	2013-11-28	Diamedica, Inc.	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en)	2012-06-04	2017-10-30	Diamedica Therapeutics Inc	Human tissue kallikrein 1 is glycosylated isoforms
CA2878991C (en)	2012-07-23	2021-12-07	Zealand Pharma A/S	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR101336499B1 (ko) *	2013-03-06	2013-12-03	씨제이제일제당 (주)	당뇨병의 예방 또는 치료용 복합 조성물
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
PT3057984T (pt)	2013-10-17	2018-10-24	Boehringer Ingelheim Int	Análogos de glucagon acilados
JP2017503474A (ja)	2013-11-06	2017-02-02	ジーランドファーマアクティーゼルスカブ	グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
MX2016005556A (es)	2013-11-06	2016-07-15	Zealand Pharma As	Compuestos agonistas duales de gip-glp-1 y procedimientos.
WO2015128453A1 (en)	2014-02-28	2015-09-03	Boehringer Ingelheim International Gmbh	Medical use of a dpp-4 inhibitor
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10253078B2 (en)	2014-10-29	2019-04-09	Zealand Pharma A/S	GIP agonist compounds and methods
DK3283507T3 (da)	2015-04-16	2020-01-02	Zealand Pharma As	Acyleret glucagonanalog
US10155000B2 (en)	2016-06-10	2018-12-18	Boehringer Ingelheim International Gmbh	Medical use of pharmaceutical combination or composition
EP4424320A3 (en)	2016-12-09	2025-06-11	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
EP3592377A4 (en)	2017-03-09	2021-02-17	Diamedica Inc.	TISSUE KALLICREIN DOSAGE FORMS 1
CA3073838A1 (en)	2017-08-30	2019-03-07	Pendulum Therapeutics, Inc.	Methods and compositions for treatment of microbiome-associated disorders
CA3113684A1 (en) *	2018-09-24	2020-04-02	Pendulum Therapeutics, Inc.	Microbial compositions and methods of use
DK4056176T3 (da)	2018-09-24	2024-05-06	Amarin Pharmaceuticals Ie Ltd	Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ
US12427134B2 (en)	2019-11-12	2025-09-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
CN113648318B (zh) *	2020-05-12	2023-08-25	中国科学院上海营养与健康研究所	增强细胞产热和治疗疾病的应用
WO2022225896A1 (en)	2021-04-21	2022-10-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3174901A (en)	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
DE2348334C2 (de)	1973-09-26	1982-11-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en)	1973-09-26	1977-11-29	Boehringer Mannheim G.M.B.H.	Rapidly resorbable glibenclamide
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
EP0062704A1 (de)	1980-12-03	1982-10-20	Hoechst Aktiengesellschaft	Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US4916163A (en)	1985-06-04	1990-04-10	The Upjohn Company	Spray-dried lactose formulation of micronized glyburide
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3833439A1 (de)	1988-10-01	1991-09-12	Hoechst Ag	Verfahren zur mikronisierung von glibenclamid
US5258185A (en) *	1989-08-23	1993-11-02	Bauer Kurt H	Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
DE4323636A1 (de)	1993-07-15	1995-01-19	Hoechst Ag	Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en)	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it)	1995-11-14	1997-10-27	Gentili Ist Spa	Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) *	1997-02-19	2000-01-04	Warner-Lambert Company	Combinations for diabetes
US6153632A (en)	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
CA2290624C (en) *	1997-06-06	2006-12-05	John W. Shell	Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
AU7906898A (en)	1997-06-13	1998-12-30	Novo Nordisk A/S	Novel niddm regimen
CA2294582C (en)	1997-06-18	2008-02-12	Smithkline Beecham P.L.C.	Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en)	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
EP1030665A4 (en)	1997-10-17	2002-11-27	Aventis Pharm Prod Inc	THERAPEUTIC USE OF CHINOLINE DERIVATIVES
CA2312990C (en)	1997-12-08	2008-04-29	Bristol-Myers Squibb Company	Novel salts of metformin and method
FR2774591B1 (fr)	1998-02-12	2000-05-05	Lipha	Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FI111167B (fi) *	1998-02-24	2003-06-13	Kemira Chemicals Oy	Menetelmä lietteen säilyvyyden parantamiseksi
WO1999043705A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
ATE250418T1 (de)	1998-07-15	2003-10-15	Merck Sante Sas	Tabletten enthaltend eine kombination von glibenclamid und metformin
TR200100773T2 (tr)	1998-09-17	2001-07-23	Bristol-Myers Squibb Company	Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi
CO5200844A1 (es)	1999-09-17	2002-09-27	Novartis Ag	Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
EP2620443A1 (en)	2012-01-25	2013-07-31	Galecto Biotech AB	Novel galactoside inhibitors of galectins

1999
- 1999-11-03 US US09/432,465 patent/US6586438B2/en not_active Expired - Lifetime
- 1999-12-14 US US09/460,920 patent/US7598262B2/en not_active Expired - Lifetime
2000
- 2000-10-13 GE GE4802A patent/GEP20053539B/en unknown
- 2000-10-13 SK SK499-2002A patent/SK4992002A3/sk not_active Application Discontinuation
- 2000-10-13 HK HK02107208.1A patent/HK1045655A1/zh unknown
- 2000-10-13 EE EEP200200241A patent/EE05210B1/et not_active IP Right Cessation
- 2000-10-13 CN CN2008100817553A patent/CN101273981B/zh not_active Expired - Lifetime
- 2000-10-13 UA UA2002054480A patent/UA76706C2/uk unknown
- 2000-10-13 IL IL14913800A patent/IL149138A0/xx active IP Right Grant
- 2000-10-13 CA CA002389931A patent/CA2389931A1/en not_active Abandoned
- 2000-10-13 JP JP2001534363A patent/JP2003529551A/ja active Pending
- 2000-10-13 WO PCT/US2000/028467 patent/WO2001032158A2/en not_active Ceased
- 2000-10-13 CZ CZ20021547A patent/CZ20021547A3/cs unknown
- 2000-10-13 KR KR1020027005677A patent/KR20020050253A/ko not_active Ceased
- 2000-10-13 GE GE4798A patent/GEP20053538B/en unknown
- 2000-10-13 AU AU80229/00A patent/AU781781B2/en not_active Ceased
- 2000-10-13 RU RU2002113764/15A patent/RU2276604C2/ru not_active IP Right Cessation
- 2000-10-13 ES ES00972122T patent/ES2302702T3/es not_active Expired - Lifetime
- 2000-10-13 BR BR0015295-1A patent/BR0015295A/pt not_active Application Discontinuation
- 2000-10-13 RO ROA200200560A patent/RO123109B1/ro unknown
- 2000-10-13 UA UA2002054481A patent/UA75583C2/uk unknown
- 2000-10-13 CN CN2011101796999A patent/CN102283853A/zh active Pending
- 2000-10-13 DE DE60038455T patent/DE60038455T2/de not_active Expired - Lifetime
- 2000-10-13 CN CNB008180288A patent/CN100386114C/zh not_active Expired - Lifetime
- 2000-10-13 CZ CZ20021546A patent/CZ304090B6/cs not_active IP Right Cessation
- 2000-10-13 PL PL00366112A patent/PL366112A1/xx not_active Application Discontinuation
- 2000-10-13 NZ NZ552074A patent/NZ552074A/en not_active IP Right Cessation
- 2000-10-13 HU HU0300642A patent/HUP0300642A3/hu unknown
- 2000-10-13 KR KR1020027005673A patent/KR100769786B1/ko not_active Expired - Lifetime
- 2000-10-13 EP EP00970913A patent/EP1253944A2/en not_active Withdrawn
- 2000-10-13 MX MXPA02004290A patent/MXPA02004290A/es not_active Application Discontinuation
- 2000-10-24 MY MYPI20004996A patent/MY125118A/en unknown
- 2000-10-24 MY MYPI20004995A patent/MY136636A/en unknown
- 2000-10-27 TN TNTNSN00206A patent/TNSN00206A1/en unknown
- 2000-10-27 TW TW089122629A patent/TWI241185B/zh not_active IP Right Cessation
- 2000-10-27 TN TNTNSN00207A patent/TNSN00207A1/en unknown
- 2000-11-02 UY UY26425A patent/UY26425A1/es unknown
- 2000-11-03 AR ARP000105804A patent/AR026355A1/es unknown
2002
- 2002-04-15 IL IL149139A patent/IL149139A/en active IP Right Grant
- 2002-04-15 IL IL149138A patent/IL149138A/en not_active IP Right Cessation
- 2002-04-26 ZA ZA200203367A patent/ZA200203367B/xx unknown
- 2002-04-26 ZA ZA200203368A patent/ZA200203368B/xx unknown
- 2002-05-02 NO NO20022086A patent/NO20022086L/no unknown
- 2002-05-22 BG BG106732A patent/BG106732A/bg unknown
- 2002-05-22 BG BG106733A patent/BG65850B1/bg unknown
- 2002-05-24 LT LT2002062A patent/LT5025B/lt not_active IP Right Cessation
- 2002-06-03 LV LVP-02-93A patent/LV12907B/en unknown
2012
- 2012-09-25 JP JP2012211400A patent/JP2013028631A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
TNSN00206A1 (en)	2005-11-10
LT2002062A (en)	2003-03-25
CN101273981A (zh)	2008-10-01
UA75583C2 (uk)	2006-05-15
MXPA02004290A (es)	2003-02-12
SK4992002A3 (en)	2003-04-01
BG106732A (bg)	2003-02-28
IL149139A (en)	2011-11-30
PL366112A1 (en)	2005-01-24
MY136636A (en)	2008-11-28
KR20020050253A (ko)	2002-06-26
KR20020057994A (ko)	2002-07-12
TWI241185B (en)	2005-10-11
WO2001032158A3 (en)	2002-08-29
NO20022086L (no)	2002-06-24
CZ20021547A3 (cs)	2003-01-15
EE05210B1 (et)	2009-10-15
HK1045655A1 (zh)	2002-12-06
CZ304090B6 (cs)	2013-10-16
LV12907B (en)	2003-08-20
CN100386114C (zh)	2008-05-07
CN1414862A (zh)	2003-04-30
DE60038455D1 (de)	2008-05-08
IL149138A0 (en)	2002-11-10
RU2276604C2 (ru)	2006-05-20
BG65850B1 (bg)	2010-03-31
DE60038455T2 (de)	2009-04-23
US7598262B2 (en)	2009-10-06
US20020177602A1 (en)	2002-11-28
RO123109B1 (ro)	2010-11-30
JP2013028631A (ja)	2013-02-07
AU8022900A (en)	2001-05-14
LT5025B (lt)	2003-06-25
IL149138A (en)	2007-12-03
ZA200203367B (en)	2003-09-10
WO2001032158A2 (en)	2001-05-10
HUP0300642A2 (hu)	2003-07-28
KR100769786B1 (ko)	2007-10-24
EP1253944A2 (en)	2002-11-06
CN102283853A (zh)	2011-12-21
TNSN00207A1 (en)	2005-11-10
CA2389931A1 (en)	2001-05-10
BG106733A (bg)	2003-02-28
ES2302702T3 (es)	2008-08-01
NZ552074A (en)	2008-06-30
US6586438B2 (en)	2003-07-01
AR026355A1 (es)	2003-02-05
UA76706C2 (uk)	2006-09-15
UY26425A1 (es)	2001-07-31
GEP20053538B (en)	2005-06-10
NO20022086D0 (no)	2002-05-02
HUP0300642A3 (en)	2006-05-29
ZA200203368B (en)	2003-09-02
RU2002113764A (ru)	2004-03-20
US20020183345A1 (en)	2002-12-05
GEP20053539B (en)	2005-06-10
CN101273981B (zh)	2011-01-26
BR0015295A (pt)	2003-06-24
JP2003529551A (ja)	2003-10-07
AU781781B2 (en)	2005-06-16
MY125118A (en)	2006-07-31

Publication	Publication Date	Title
EE200200241A (et)	2003-12-15	Suhkurtõvevastane preparaat ja meetod
NO20022334L (no)	2002-07-09	Ny sammensetning og anvendelse
NO20032753D0 (no)	2003-06-17	Forbindelse og anvendelse derav
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
DE60031119D1 (de)	2006-11-16	Richtbohrvorrichtung und -verfahren
FI974494L (fi)	1999-06-12	Paikannusmenetelmä ja paikannusjärjestely
DK1454907T3 (da)	2009-03-09	Quninazolin og pyridopyrmidin-derivativer
DE60014208D1 (de)	2004-11-04	Druckvorrichtung und -verfahren
DE60020737D1 (de)	2005-07-14	Sic-einkristall und herstellungsverfahren dafür
DE60032898D1 (de)	2007-02-22	Arylthiazolidindion- und aryloxazolidinderivate
NO20006488D0 (no)	2000-12-19	Sammensetning og anvendelse
DE69904731D1 (de)	2003-02-06	Feinzerkleinerer und feinzerkleinerungsverfahren
DE60039547D1 (de)	2008-08-28	Bestückungsverfahren und Bestückungsvorrichtung
EE200200282A (et)	2003-06-16	Keemilised meetodid ja vaheühendid
FI19992807L (fi)	2001-06-30	Menetelmä ja järjestely häiriön poistamiseksi
EP1067925A4 (en)	2003-04-16	ANTIDIABETIC CONNECTIONS
DE60025502D1 (de)	2006-04-06	Sic-einkristall und herstellungsverfahren dafür
FI19992513L (fi)	2001-05-26	Menetelmä ja laite rullanvaihdossa
DE60014484D1 (de)	2004-11-11	Anreiss-Vorrichtung und -Verfahren
DE60024667D1 (de)	2006-01-12	Sic-einkristall und herstellungsverfahren dafür
FI990973A7 (fi)	2000-10-30	Harvesteripää ja menetelmä siinä
FI19992817L (fi)	2001-07-01	Rakennustekninen menetelmä ja laite
FI19992294L (fi)	2001-04-23	Järjestely ja menetelmä sanan pituuden rajoittamiseksi
FI991365L (fi)	2000-12-16	Valkaisuaktivaattori ja menetelmä aktivaattorin käyttämiseksi
FI990554L (fi)	2000-09-13	Monitorointimenetelmä ja monitorointijärjestely

Legal Events

Date	Code	Title	Description
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2014-06-16	MM4A	Lapsed by not paying the annual fees	Effective date: 20131013